Indivior (INDV) Expected to Announce Earnings on Thursday

Indivior (NASDAQ:INDV) will likely be releasing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Indivior to post earnings of $0.38 per share and revenue of $257.66 million for the quarter. Indivior has set its FY 2025 guidance at EPS.Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, July 31st. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.25. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%.The business had revenue of $302.00 million for the quarter, compared to the consensus estimate of $239.43 million. On average, analysts expect Indivior to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Indivior Price Performance

INDV stock opened at $24.78 on Tuesday. Indivior has a twelve month low of $7.62 and a twelve month high of $25.49. The business’s 50-day simple moving average is $23.99 and its 200 day simple moving average is $17.70.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INDV. Goldman Sachs Group Inc. lifted its stake in Indivior by 18.4% during the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares during the period. Rubric Capital Management LP raised its stake in shares of Indivior by 31.6% in the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock valued at $68,499,000 after acquiring an additional 1,117,140 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after acquiring an additional 958,132 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Indivior by 669.1% in the second quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock valued at $5,769,000 after acquiring an additional 340,498 shares during the last quarter. Finally, Jump Financial LLC bought a new position in shares of Indivior in the second quarter valued at approximately $2,748,000. Institutional investors own 60.33% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 3rd. HC Wainwright assumed coverage on Indivior in a research report on Wednesday, August 6th. They set a “buy” rating and a $27.00 target price on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Indivior in a research report on Wednesday, October 8th. Craig Hallum lifted their target price on Indivior from $27.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Finally, Jefferies Financial Group initiated coverage on Indivior in a research report on Tuesday, July 22nd. They set a “buy” rating and a $20.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.00.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.